Keywords: osi-7904l, ph, ii, gastric, cancer, usa-based, osi
OSI-7904L in Ph II for gastric cancer
Article | 03 November 2003
USA-based OSI Pharmaceuticals has initiated a Phase II clinical study ofOSI-7904L, an investigational anticancer drug, in patients with previously ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
